You are here: Industry Insights > retinal disease

News List

More Patients Set to Benefit as Kanghong Pharmaceutical Targets New Indications with Conbercept prnasia
February 04, 2021
Chengdu Kanghong Pharmaceutical Group, has received Special Protocol Assessments from the Food and Drug Administration for three new indications for its biologic drug conbercept.
Samsung Biologics signs strategic partnership with Kanaph Therapeutics to develop treatment for retinal diseases prnasia
September 27, 2020
Samsung Biologics and Kanaph Therapeutics have entered into a strategic partnership to develop KNP-301, a bi-specific Fc fusion protein intended to treat retinal diseases.
JCyte signs ex-US licensing deal with Santen for retinal disease therapy pharmaceutical-business-review
May 13, 2020
JCyte has signed an ex-US licensing deal with Japanese ophthalmic company Santen Pharmaceutical worth up to $252m to develop and commercialise its investigational jCell therapy for a rare genetic eye disorder called retinitis pigmentosa.
OXB and Santen to develop gene therapy products for retinal disease pharmaceutical-technology
June 27, 2019
Oxford Biomedica (OXB) and Santen Pharmaceutical have agreed to jointly conduct research and development (R&D) activities for gene therapy products.
EU OKs Novartis’ gene therapy Luxturna for rare retinal disease pharmatimes
November 26, 2018
Novartis’ Luxturna has been approved by regulators in Europe to treat a rare inherited condition that causes sight loss.
Germany’s Evotec and CRTD to find new therapies for retinal diseases pharmaceutical-technology
December 18, 2017
German drug discovery company Evotec and the Centre for Regenerative Therapies TU Dresden (CRTD) have entered a research collaboration to discover new small molecule candidates for the treatment of retinal diseases.